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In November 2013, with an update in 2014, the American College of Cardiology (ACC) and American Heart Association (AHA) released clinical practice guidelines for the treatment of blood cholesterol to reduce cardiovascular risk.[1](#jah31627-bib-0001){ref-type="ref"}, [2](#jah31627-bib-0002){ref-type="ref"} These guidelines aimed to replace the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III guidelines. Compared with the 2004 ATP III guidelines, which involved risk‐based low‐density lipoprotein cholesterol (LDL‐C) thresholds for treatment of coronary heart disease (CHD) alone, the ACC/AHA guidelines focus more on the treatment of absolute cardiovascular risk and was broadened to estimate the 10‐year risk of all atherosclerotic cardiovascular diseases (ASCVDs), including CHD and stroke, using Pooled Cohort Equations.[1](#jah31627-bib-0001){ref-type="ref"}, [2](#jah31627-bib-0002){ref-type="ref"} The application of the ACC/AHA guidelines largely expanded the number of adults endorsed for statin treatment attributed to a lower cut‐off point of 7.5%, and there have been debates about whether the ACC/AHA guidelines have set too low an ASCVD risk threshold for statin therapy eligibility.[3](#jah31627-bib-0003){ref-type="ref"}, [4](#jah31627-bib-0004){ref-type="ref"}

A few studies have compared statin assignment between the ACC/AHA and ATP III guidelines in subjects with coronary atherosclerosis detected by coronary computed tomography angiography (CCTA).[5](#jah31627-bib-0005){ref-type="ref"}, [6](#jah31627-bib-0006){ref-type="ref"}, [7](#jah31627-bib-0007){ref-type="ref"}, [8](#jah31627-bib-0008){ref-type="ref"} Two studies performed the comparative analysis between these 2 guidelines in Korean population, and their results showed that the ACC/AHA was more sensitive in identifying subjects with subclinical atherosclerosis as assessed by coronary artery calcification (CAC) score than the previous ATP III guidelines.[7](#jah31627-bib-0007){ref-type="ref"}, [8](#jah31627-bib-0008){ref-type="ref"} However, these previous studies analyzed a single measurement of CAC score, and the alignment of the 2 guidelines for statin therapy with CAC score progression has not been previously reported. Although baseline CAC score measured by CCTA has been established as a surrogate marker of coronary atherosclerosis, recent studies have shown that CAC score progression is significantly related to an increased risk of future cardiovascular events and all‐cause mortality and a better predictor of cardiovascular events and prognosis than baseline CAC score.[9](#jah31627-bib-0009){ref-type="ref"}, [10](#jah31627-bib-0010){ref-type="ref"}

In light of these findings, we sought to evaluate the accuracy of the ATP III and ACC/AHA guidelines in assigning statin therapy to subjects with CAC score progression, in an asymptomatic, middle‐aged, Korean population without history of CHD.

Methods {#jah31627-sec-0005}
=======

Study Population {#jah31627-sec-0006}
----------------

The study population consisted of 7300 individuals who underwent baseline CCTA using a 64‐slice multidetector computed tomography (MDCT) scanner during routine health evaluations at Asan Medical Center (Seoul, Republic of Korea) between January 2007 and June 2011. Among these 7300 participants, repeated CCTA was performed in 1591 cases through December 2014. This analysis also used data obtained using in‐person follow‐up examinations after the baseline examinations. Each participant completed a questionnaire that covered the history of previous medical and/or surgical diseases, medications, and drinking and smoking habits. Drinking habits were categorized in terms of frequency per week (ie, ≤1 times/week or ≥2 times/week \[moderate drinker\]), smoking habits as noncurrent or current, and exercise habits as frequency per week (ie, ≤2 times/week or ≥3 times/week \[physically active\]).

Cardiovascular disease (CVD) history was based on each participant\'s history of physician‐diagnosed angina, myocardial infarction, and/or cerebrovascular accidents. Participants with diabetes mellitus were defined as those with a fasting plasma glucose (FPG) level of ≥7.0 mmol/L and/or a hemoglobin A1c (HbA1c) level ≥6.5%.[11](#jah31627-bib-0011){ref-type="ref"} In addition, participants who reported the use of antidiabetic medications on a self‐report questionnaire were considered to have diabetes mellitus.[12](#jah31627-bib-0012){ref-type="ref"} Hypertension was defined as systolic and/or diastolic blood pressure (BP) ≥140/90 mm Hg or the use of hypertensive medications.

We excluded participants with a history of CVD at baseline examinations (n=95), as well as participants receiving statins (n=238). Participants who underwent percutaneous coronary intervention (n=8) or coronary arterial bypass surgery (n=3) after the initial examinations were also excluded. Finally, subjects that were not between the ages of 20 and 79 years were excluded (n=3). Some participants met more than 2 exclusion criteria. After excluding ineligible subjects, 1246 subjects with a mean age of 54.2 years (range, 33--79) were enrolled in our final study population. All participants provided written informed consent. This study was approved by the institutional review board of Asan Medical Center.

Assignment to Statin Therapy According to the 2004 ATP III Guidelines {#jah31627-sec-0007}
---------------------------------------------------------------------

Because we excluded subjects with known CVD, no subject had CHD or stroke at the time of enrollment. Diabetes mellitus was regarded as a CHD risk equivalent.[13](#jah31627-bib-0013){ref-type="ref"} CHD risk factors included smoking, hypertension, low high‐density lipoprotein cholesterol (HDL‐C; \<1.0 mmol/L), family history of premature CHD (ie, CHD in a male first‐degree relative \<55 years of age; CHD in a female first‐degree relative \<65 years of age), and age (men≥45 years; women≥55 years).[13](#jah31627-bib-0013){ref-type="ref"} The 10‐year risk for CHD was calculated using the modified Framingham risk scoring (FRS) system.[14](#jah31627-bib-0014){ref-type="ref"} Subjects assigned to statin therapy according to the ATP III guidelines included those categorized as: (1) high risk (CHD risk equivalents or CHD risk factors ≥2 and 10‐year risk for CHD \>20%) with an LDL‐C level of ≥2.6 mmol/L; (2) moderately high risk (CHD risk factors ≥2 and 10‐year risk for CHD 10--20%) with an LDL‐C level of ≥3.4 mmol/L; (3) moderate risk (CHD risk factors ≥2 and 10‐year risk for CHD \<10%) with an LDL‐C level of ≥4.1 mmol/L; and (4) lower risk (0--1 CHD risk factors) with an LDL‐C level of ≥4.9 mmol/L.[13](#jah31627-bib-0013){ref-type="ref"}

Assignment to Statin Therapy According to the 2013 ACC/AHA Guidelines {#jah31627-sec-0008}
---------------------------------------------------------------------

Based on the exclusion criteria, no subject included in this study had CVD at the time of enrollment. Subjects who were recommended statin therapy for primary prevention included (1) adults ≥21 years of age with primary elevations in LDL‐C ≥4.9 mmol/L, (2) patients with diabetes mellitus aged 40 to 75 years with an LDL‐C level of 1.8 to 4.9 mmol/L, (3) individuals aged 40 to 75 years with no clinical ASCVD or diabetes with an LDL--C of 1.8 to 4.9 mmol/L and estimated 10‐year ASCVD risk of ≥7.5%, and (4) nondiabetic individuals with 5% to \<7.5% 10‐year ASCVD risk among 40 to 75 years of age with LDL‐C 1.8 to 4.9 mmol/L.[1](#jah31627-bib-0001){ref-type="ref"} The 10‐year ASCVD risk was estimated using the Pooled Cohort Equations for non‐Hispanic white developed by the Risk Assessment Work Group.[1](#jah31627-bib-0001){ref-type="ref"} Parameters required for Pooled Cohort Equations included sex, age, race, total cholesterol, HDL‐C, systolic BP, use of antihypertensive medication, diabetes mellitus, and smoking.[1](#jah31627-bib-0001){ref-type="ref"} The Pooled Cohort Equations were not applied to subjects younger than 40 years or older than 75 years.[1](#jah31627-bib-0001){ref-type="ref"}

Clinical and Laboratory Measurements {#jah31627-sec-0009}
------------------------------------

Height and weight were obtained while the participants wore light clothing without shoes. Body mass index (BMI) was calculated as weight in kilograms divided by the square of the height in meters. Waist circumference (WC; in cm) was measured midway between the costal margin and the iliac crest at the end of a normal expiration. BP was measured on the right arm after ≥5‐minute rests using an automatic manometer with an appropriate cuff size. After overnight fasting, early‐morning blood samples were drawn from the antecubital vein into vacuum tubes and subsequently analyzed by the central certified laboratory at Asan Medical Center. Measurements included the concentrations of fasting glucose, insulin, high‐sensitivity C‐reactive protein (hsCRP), several lipid parameters, and liver enzymes. The methods used were detailed previously.[15](#jah31627-bib-0015){ref-type="ref"}

Use of MDCT to Assess the CAC Score {#jah31627-sec-0010}
-----------------------------------

MDCT examinations were performed by using either 64‐slice, single‐source, computed tomography (CT; LightSpeed VCT; GE, Milwaukee, WI) or dual‐source CT (Somatom Definition or Somatom Definition Flash; Siemens, Erlangen, Germany), as previously described.[16](#jah31627-bib-0016){ref-type="ref"}, [17](#jah31627-bib-0017){ref-type="ref"} The CAC score was calculated using an automated software program using the Agatston scoring method,[18](#jah31627-bib-0018){ref-type="ref"} and participants were categorized according to the cut‐off points used by Greenland et al.[19](#jah31627-bib-0019){ref-type="ref"} (ie, none, 0; mild, 1--100; moderate, 101--300; severe, \>300).

Estimating Changes in the CAC Score {#jah31627-sec-0011}
-----------------------------------

Progression of CAC was defined as (1) incident CAC, which indicates baseline Agatston score of zero converting to detectable CAC at the follow‐up examination in a population free of CAC at baseline,[20](#jah31627-bib-0020){ref-type="ref"}, [21](#jah31627-bib-0021){ref-type="ref"} or (2) increase of ≥2.5 units between the baseline and final square root of CAC scores participants who had detectable CAC at baseline examination.[9](#jah31627-bib-0009){ref-type="ref"}, [22](#jah31627-bib-0022){ref-type="ref"}, [23](#jah31627-bib-0023){ref-type="ref"} To eliminate the dependence of residual interscan variability on the baseline CAC score, square root transformation of the CAC score was performed before the estimation of CAC progression. Using the data published by Hokanson et al., progressors were defined as individuals with a difference of ≥2.5 units between the baseline and final square root of their CAC scores (ie, the "SQRT method" \[the square root‐transformed difference\]).[9](#jah31627-bib-0009){ref-type="ref"}, [22](#jah31627-bib-0022){ref-type="ref"}, [23](#jah31627-bib-0023){ref-type="ref"} To put it differently, a change of \<2.5 units between the baseline and final square root of the CAC score was considered to be within the margin of error for the estimation of the CAC score using MDCT and thus was attributed to interscan variability; such participants were classified as nonprogressors.[9](#jah31627-bib-0009){ref-type="ref"}, [22](#jah31627-bib-0022){ref-type="ref"}, [23](#jah31627-bib-0023){ref-type="ref"}

Statistical Analysis {#jah31627-sec-0012}
--------------------

Continuous variables with normal distributions are expressed as the mean±SD, whereas continuous variables with skewed distributions are expressed as the median (and interquartile range). Categorical variables are expressed as the percentage. After we categorized participants according to the CAC score progression, the demographic and biochemical characteristics of subgroups were compared using the Student *t* test or Mann--Whitney *U* test for continuous variables or the chi‐squared test for categorical variables.

Logistic regression analysis was performed to calculate the odds ratios (ORs) and 95% CIs of the 2 guidelines on statin eligibility for the prediction of CAC progression. C statistics, which are analogous to the area under the receiver operating characteristic (ROC) curve, were calculated to compare the ability of different logistic models to discriminate between the 2 sets of criteria for the prediction of CAC score progression.[24](#jah31627-bib-0024){ref-type="ref"} Comparison between the 2 C statistics was performed by MedCalc software (version 11.6.1.0 for Windows; MedCalc Software, Mariakerke, Belgium) according to the method described by DeLong et al.[10](#jah31627-bib-0010){ref-type="ref"}

Next, to compare the 2 risk assessment methods (ie, FRS system and the estimated 10‐year ASCVD risk) for the prediction of CAC score progression, we plotted ROC curves and calculated the areas under the curve (AUCs). The Youden index was used to identify the best cut‐off point. Comparisons of ROC curves were performed using the method of DeLong et al.,[10](#jah31627-bib-0010){ref-type="ref"} as mentioned above. All statistical analyses, except ROC curves, were performed using SPSS software (version 20.0 for Windows; SPSS, Inc., Chicago, IL). In our current analyses, *P* \< 0.05 was considered statistically significant.

Results {#jah31627-sec-0013}
=======

Clinical and Biochemical Characteristics of the Study Subjects {#jah31627-sec-0014}
--------------------------------------------------------------

Baseline characteristics of the study population according to CAC score progression are listed in Table [1](#jah31627-tbl-0001){ref-type="table-wrap"}. Overall, mean age was 54.2±7.4 years and males predominated (81.8%). Compared with nonprogressors, progressors were significantly older and had a higher BMI, WC, and systolic and diastolic BP. In addition, progressors were more likely to be male, current smokers, and frequent drinkers. Progressors also had a less‐favorable risk profile, which included higher prevalences of hypertension and diabetes mellitus and higher levels of FPG, HbA1c, triglycerides (TG), uric acid, aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma‐glutamyltransferase (GGT), and hsCRP. The 10‐year FRS and 10‐year ASCVD risk score were significantly higher in progressors than nonprogressors (Table [1](#jah31627-tbl-0001){ref-type="table-wrap"}).

###### 

Clinical and Biochemical Characteristics of the Study Participants According to CAC Score Progression

                                            Total             Nonprogressor     Progressor         *P* Value
  ----------------------------------------- ----------------- ----------------- ------------------ -----------
  N (%)                                     1,246             933 (74.9)        313 (25.1)         --
  Age, y                                    54.2±7.4          53.5±7.1          56.3±7.9           \<0.001
  Sex (% male)                              81.8              78.3              92.0               \<0.001
  BMI, kg/m^2^                              25.0±3.0          24.8±3.1          25.4±2.6           0.002
  WC, cm                                    87.0±8.2          86.3±8.3          89.0±7.4           \<0.001
  Systolic BP, mm Hg                        119.6±12.8        118.7±12.4        122.4±13.6         \<0.001
  Diastolic BP, mm Hg                       76.8±10.5         76.2±10.4         78.4±10.8          0.002
  Current smoker (%)                        27.3              25.0              36.2               0.002
  Moderate drinker (%)                      52.8              51.0              58.1               0.031
  Physically active (%)                     43.6              42.1              47.6               0.100
  Family history of diabetes mellitus (%)   24.4              23.8              26.2               0.403
  Diabetes mellitus, n (%)                  168 (13.5)        105 (11.3)        63 (20.1)          \<0.001
  Hypertension, n (%)                       420 (33.7)        277 (29.7)        143 (45.7)         \<0.001
  FPG, mmol/L                               5.8±1.0           5.8±1.0           6.0±1.1            \<0.001
  HbA1c (%)                                 5.5 (5.3--5.9)    5.5 (5.3--5.8)    5.6 (5.3--6.0)     0.005
  Total cholesterol, mmol/L                 5.1±0.8           5.1±0.8           5.1±0.9            0.565
  TG, mmol/L                                1.3 (0.9--1.8)    1.3 (0.9--1.8)    1.4 (1.0--1.8)     0.027
  LDL‐C, mmol/L                             3.3±0.7           3.2±0.7           3.3±0.7            0.750
  HDL‐C, mmol/L                             1.3±0.3           1.6±0.3           1.3±0.3            0.006
  Uric acid, μmol/L                         344.9±82.6        340.7±83.2        357.6±79.4         0.002
  AST, U/L                                  25 (22--31)       25 (21--31)       27 (22--33)        0.001
  ALT, U/L                                  23 (17--31)       22 (17--31)       24 (19--34)        \<0.001
  GGT, U/L                                  25 (16--40)       24 (16--38)       30 (20--44)        \<0.001
  hsCRP, mg/L                               0.6 (0.3--1.3)    0.6 (0.3--1.3)    0.7 (0.4--1.5)     0.049
  10‐year FRS (%)                           6.0 (3.0--10.0)   6.0 (2.0--10.0)   10.0 (6.0--12.0)   \<0.001
  10‐year ASCVD risk score (%)              5.6 (2.7--9.8)    4.8 (2.3--8.7)    8.1 (4.9--13.4)    \<0.001
  Baseline CAC score                        0 (0--23)         0 (0--11)         12 (0--98)         \<0.001
  Last follow‐up CAC score                  1 (0--50)         0 (0--16)         64 (11--234)       \<0.001
  Baseline CAC score category                                                                      
  0, n (%)                                  714 (57.3)        602 (64.5)        112 (35.8)         \<0.001
  1 to 100, n (%)                           385 (30.9)        258 (27.7)        127 (40.6)         
  101 to 300, n (%)                         93 (7.5)          49 (5.3)          44 (14.1)          
  \>300, n (%)                              54 (4.3)          24 (2.6)          30 (9.6)           
  Follow‐up interval (years)                3.0 (2.1--3.8)    2.9 (2.0--3.6)    3.1 (2.5--4.0)     \<0.001

ALT indicates alanine aminotransferase; ASCVD, atherosclerotic cardiovascular disease; AST, aspartate aminotransferase; BMI, body mass index; BP, blood pressure; CAC, coronary artery calcification; FPG, fasting plasma glucose; FRS, Framingham Risk Score; GGT, gamma‐glutamyltransferase; HbA1c, hemoglobin A1c; HDL‐C, high‐density lipoprotein cholesterol; hsCRP, high‐sensitivity C‐reactive protein; LDL‐C, low‐density lipoprotein cholesterol; TG, triglyceride; WC, waist circumference.

\*Continuous variables with normal distributions are expressed as the mean±SD, whereas continuous variables with skewed distributions are expressed as the median (and interquartile range). Categorical variables are expressed as the percentage (%).

Statin Eligibility According to the 2004 ATP III and 2013 ACC/AHA Guidelines {#jah31627-sec-0015}
----------------------------------------------------------------------------

When the ATP III and ACC/AHA guidelines were each applied separately to the study population, 256 (20.5%) and 681 (54.7%) of subjects were eligible for statin therapy, respectively (Figures [1](#jah31627-fig-0001){ref-type="fig"} and [2](#jah31627-fig-0002){ref-type="fig"}). In subjects who were older than 60 years, 84.5% of the subjects were eligible for statins according to ACC/AHA guidelines compared with 26.1% recommendation by ATP III guidelines (Figure [1](#jah31627-fig-0001){ref-type="fig"}B). The increase in statin eligibility was mainly observed in subjects eligible for statins attributed to an increase in the risk predicted by the risk calculator (Figure [1](#jah31627-fig-0001){ref-type="fig"}).

![A, Flow diagram of participants who would be eligible for statin therapy according to each set of guidelines and age group. B, Proportion of participants who would be eligible for statin therapy according to each set of guidelines and age group. Proportions were calculated within the total population (N=1289). \*"Statin considered" indicates statin candidates who are nondiabetic individuals with 5% to \<7.5% 10‐year ASCVD risk among 40 to 75 years of age with LDL‐C 1.8 to 4.9 mmol/L. ACC/AHA indicates American College of Cardiology/American Heart Association; ASCVD, atherosclerotic cardiovascular disease; ATP III, Adult Treatment Panel III; LDL‐C, low‐density lipoprotein cholesterol.](JAH3-5-e003410-g001){#jah31627-fig-0001}

![Comparison of the proportion of nonprogressor and progressor in statin‐eligible population according to each set of guideline. Proportions were calculated within the total population (N=1289). ACC/AHA indicates American College of Cardiology/American Heart Association; ATP III, Adult Treatment Panel III; Not Rec, not recommended for statin; Rec, Recommended for statin.](JAH3-5-e003410-g002){#jah31627-fig-0002}

Subjects who were eligible for statin under ACC/AHA guideline tended to be older. On the other hand, subjects who were eligible for statin under ATP III guidelines are more likely to be current smokers and less physically active than statin‐eligible subjects according to ACC/AHA guidelines. Statin eligible subjects under ATP III guidelines also have higher prevalence of hypertension and diabetes mellitus, more frequent family history of diabetes mellitus, and worse lipid profiles (Table [2](#jah31627-tbl-0002){ref-type="table-wrap"}). Statin‐eligible subjects by ACC/AHA guidelines tended to have higher baseline and last follow‐up CAC score (Table [3](#jah31627-tbl-0003){ref-type="table-wrap"}).

###### 

Clinical and Biochemical Characteristics of the Study Participants According to the 2004 ATP III and 2013 ACC/AHA Guidelines

                                            Statin‐Eligible by ATP‐III Guidelines   Statin‐Eligible by ACC/AHA Guidelines
  ----------------------------------------- --------------------------------------- ---------------------------------------
  N (%)                                     256 (20.5)                              681 (54.7)
  Age, y                                    55.8±7.1                                57.0±7.1
  Sex (% male)                              92.2                                    94.6
  BMI, kg/m^2^                              25.5±2.6                                25.4±3.0
  WC, cm                                    89.1±6.9                                89.2±7.4
  Systolic BP, mm Hg                        123.5±13.7                              122.4±12.7
  Diastolic BP, mm Hg                       79.7±11.2                               79.0±10.4
  Current smoker (%)                        48.8                                    41.9
  Moderate drinker (%)                      55.1                                    57.7
  Physically active (%)                     40.6                                    43.9
  Family history of diabetes mellitus (%)   34.8                                    22.8
  Diabetes mellitus, n (%)                  127 (49.6)                              155 (22.8)
  Hypertension, n (%)                       132 (51.6)                              305 (44.8)
  FPG, mmol/L                               6.7±1.6                                 6.1±1.3
  HbA1c (%)                                 6.0 (5.6--6.8)                          5.7 (5.4--6.1)
  Total cholesterol, mmol/L                 5.7±0.9                                 5.2±0.8
  TG, mmol/L                                1.6 (1.2--2.2)                          1.4 (1.1--2.0)
  LDL‐C, mmol/L                             3.8±0.7                                 3.4±0.7
  HDL‐C, mmol/L                             1.2±0.3                                 1.2±0.3
  Uric acid, μmol/L                         356.5±80.2                              358.2±78.6
  AST, U/L                                  27 (22--34)                             26 (22--32)
  ALT, U/L                                  27 (20--35)                             24 (22--32)
  GGT, U/L                                  32 (22--47)                             29 (20--43)
  hsCRP, mg/L                               0.8 (0.4--1.8)                          0.8 (0.4--1.6)
  10‐year FRS (%)                           12.0 (8.0--16.0)                        10.0 (8.0--12.0)
  10‐year ASCVD risk score (%)              11.7 (8.2--17.3)                        9.0 (6.6--13.3)

ACC/AHA indicates American College of Cardiology/American Heart Association; ALT, alanine aminotransferase; ASCVD, atherosclerotic cardiovascular disease; AST, aspartate aminotransferase; ATP III, Adult Treatment Panel III; BMI, body mass index; BP, blood pressure; CAC, coronary artery calcification; FPG, fasting plasma glucose; FRS, Framingham Risk Score; GGT, gamma‐glutamyltransferase; HbA1c, hemoglobin A1c; HDL‐C, high‐density lipoprotein cholesterol; HsCRP, high‐sensitivity C‐reactive protein; LDL‐C, low‐density lipoprotein cholesterol; TG, triglyceride; WC, waist circumference.

\*Continuous variables with normal distributions are expressed as the mean±SD, whereas continuous variables with skewed distributions are expressed as the median (and interquartile range). Categorical variables are expressed as the percentage (%).

###### 

Baseline CAC Score and CAC Score Change of the Study Participants According to the 2004 ATP III and 2013 ACC/AHA Guidelines

                                Statin‐Eligible by ATP‐III Guidelines   Statin‐Eligible by ACC/AHA Guidelines
  ----------------------------- --------------------------------------- ---------------------------------------
  N (%)                         256 (20.5)                              681 (54.7)
  Baseline CAC score            3 (0--49)                               6 (0--70)
  Last follow‐up CAC score      15 (0--104)                             21 (0--131)
  Baseline CAC score category                                           
  0, n (%)                      110 (43.7)                              308 (45.2)
  1--100, n (%)                 106 (42.1)                              263 (38.6)
  101--300, n (%)               25 (9.9)                                65 (9.5)
  \>300, n (%)                  11 (4.4)                                45 (6.6)
  Follow‐up interval (years)    2.9 (2.1--3.5)                          2.9 (2.0--3.5)

ACC/AHA indicates American College of Cardiology/American Heart Association; ATP III, Adult Treatment Panel III; CAC, coronary artery calcification.

\*Continuous variables with skewed distributions are expressed as the median (and interquartile range). Categorical variables are expressed as the percentage (%).

As shown in Figure [2](#jah31627-fig-0002){ref-type="fig"}, subjects who were recommended for statin under the ACC/AHA guidelines were more likely to be progressors compared to those who were recommended for statin under ATP III guidelines (18.1 vs 7.5%). In the case of subjects who were not recommended for statin under each guideline, those who were judged based on ACC/AHA guidelines were less likely to be progressors compared to those who were assorted based on ATP III guidelines (7.0 vs 17.7%; Figure [2](#jah31627-fig-0002){ref-type="fig"}). Statistical analysis could not be performed because the 2 groups are not independent groups and some of the subjects could overlap.

Comparison of the 2 Risk Scoring Systems for Predicting CAC Score Progression {#jah31627-sec-0016}
-----------------------------------------------------------------------------

When the ORs for the presence of CAC progression were analyzed in statin‐eligible subjects by the 2 guidelines, subjects considered statin eligible by ACC/AHA guidelines showed a higher OR than those considered statin eligible according to ATP III guidelines: 2.73 (95% CI, 2.07--3.61) versus 2.00 (95% CI, 1.49--2.68; Table [4](#jah31627-tbl-0004){ref-type="table-wrap"}). The C statistic for the ACC/AHA guidelines was 0.62 (95% CI, 0.59--0.64), and use of the ATP III risk prediction model resulted in a C statistic of 0.56 (95% CI, 0.53--0.59). A significant difference was observed between the 2 guidelines in their ability to predict CAC progression (*P* = 0.006; Table [4](#jah31627-tbl-0004){ref-type="table-wrap"}).

###### 

Comparisons of the Odds Ratio of the 2 Statin Eligibility Guidelines for the Prediction of CAC Score Progression

  Guidelines Applied                      C Statistic (95% CI)   OR (95% CI)         *P* Value   *P* Value[a](#jah31627-note-0009){ref-type="fn"}
  --------------------------------------- ---------------------- ------------------- ----------- --------------------------------------------------
  Statin eligible by ATP III guidelines   0.56 (0.53--0.59)      2.00 (1.49--2.68)   \<0.001     0.0006
  Statin eligible by ACC/AHA guidelines   0.62 (0.59--0.64)      2.73 (2.07--3.61)   \<0.001     

ACC/AHA indicates American College of Cardiology/American Heart association; ATP III, Adult Treatment Panel III; CAC, coronary artery calcification; OR, odds ratio.

*P* value between ATP III guidelines and ACC/AHA guidelines. *P* value is calculated by comparison of C statistic using the method of DeLong et al.^10^

To compare the efficacy of the 10‐year FRS and 10‐year ASCVD risk scoring systems for assigning subjects to statin therapy, we further excluded subjects who were not between the ages of 40 and 75 years and those with an LDL‐C level of ≥4.9 mmol/L and/or diabetes mellitus, in whom the calculation of the 10‐year ASCVD risk is not indicated.[1](#jah31627-bib-0001){ref-type="ref"} After these exclusions, we conducted ROC curve analysis and compared the 2 risk scoring systems for their ability to accurately detect CAC progression in the remaining 1225 subjects (Table [5](#jah31627-tbl-0005){ref-type="table-wrap"}). The optimal cut‐off values for detecting CAC score progression were 5% and 4.19% in the 10‐year ASCVD scoring system and the 10‐year FRS system, respectively. The AUCs of the 10‐year ASCVD risk scores for detecting CAC progression were slightly higher than those of the 10‐year FRS system: 0.67 (95% CI 0.64--0.70) versus 0.66 (95% CI, 0.62--0.69). However, no statistically significant differences were observed between the 2 guidelines (*P *= 0.056; Table [5](#jah31627-tbl-0005){ref-type="table-wrap"}).

###### 

Comparison of the Sensitivity and Specificity of the Framingham and 10‐year ASCVD Risk Scoring Systems for the Alignment of Statin Therapy in Subjects According to CAC Score Progression

                Framingham Risk Scoring   2013 ASCVD Risk Scoring   *P* Value[a](#jah31627-note-0011){ref-type="fn"}                                                                
  ------------- ------------------------- ------------------------- -------------------------------------------------- ------------------- ------ ------ ------ ------------------- -------
  Progression   5                         76.2                      48.6                                               0.66 (0.63--0.68)   4.19   79.5   49.3   0.67 (0.64--0.70)   0.056

ASCVD indicates atherosclerotic cardiovascular disease; AUC, area under the curve.

*P* value between Framingham and 10‐year ASCVD risk scoring system. *P* value is calculated by comparison of AUCs using the method of DeLong et al.^10^

Discussion {#jah31627-sec-0017}
==========

In the present study, we observed that a higher proportion of participants were eligible for statin therapy according to ACC/AHA cholesterol treatment guidelines (54.7%) than according to ATP III guidelines (20.5%; Figure [1](#jah31627-fig-0001){ref-type="fig"}). Using CAC score progression as a surrogate marker of CHD risk, we examined the performance of the ACC/AHA guidelines and compared it with that of the ATP III guidelines to calibrate the risk of CHD. Overall, under the ACC/AHA guidelines, the probability of being assigned statin therapy better tracks CAC score progression, which has predictive value for cardiovascular events (Table [4](#jah31627-tbl-0004){ref-type="table-wrap"}).

The ACC/AHA guidelines released in 2013 have been shown to broaden statin recommendations in Western populations.[25](#jah31627-bib-0025){ref-type="ref"}, [26](#jah31627-bib-0026){ref-type="ref"} National Health and Nutrition Examination Survey data and several Korean studies reported that the ACC/AHA guidelines increased the statin‐eligible population compared with the ATP III guidelines, and the increase was mainly observed in subjects eligible for statin therapy attributed to an increased number of adults who would be classified on the basis of their 10‐year risk of a cardiovascular event calculated by the new Pooled Cohort Equations.[7](#jah31627-bib-0007){ref-type="ref"}, [8](#jah31627-bib-0008){ref-type="ref"}, [25](#jah31627-bib-0025){ref-type="ref"}, [27](#jah31627-bib-0027){ref-type="ref"} Similar to previous studies, the ACC/AHA guidelines would substantially expand the number of adults who would be eligible for statin therapy in our population (Figure [1](#jah31627-fig-0001){ref-type="fig"}), and this increase seemed to mostly occur among those who would be considered eligible according to their predicted 10‐year ASCVD risk by the new calculator, especially subjects older than 60 years (Figure [1](#jah31627-fig-0001){ref-type="fig"}).

There have been general concerns that the new guidelines overestimate risk and cause too many patients to be eligible for statins.[3](#jah31627-bib-0003){ref-type="ref"}, [4](#jah31627-bib-0004){ref-type="ref"}, [28](#jah31627-bib-0028){ref-type="ref"} However, although the ACC/AHA guidelines recommend statin to considerable population, it is less likely to miss patients who could be beneficiary of statins. Our results demonstrated that subjects who were recommended for statin under the ACC/AHA guidelines were more likely to be progressors compared to those who were recommended for statin under ATP III guidelines (18.1 vs 7.5%; Fig. [2](#jah31627-fig-0002){ref-type="fig"}). Furthermore, a review of randomized statin trials demonstrated that statin therapy is associated with a slightly increased risk of transaminase elevations, but not of myalgias, creatine kinase elevations, rhabdomyolysis, or withdrawal of therapy compared with placebo.[29](#jah31627-bib-0029){ref-type="ref"} Last, ASCVD is one of the most important global causes of morbidity and mortality, and the most important and clinically treatable risk factor is LDL‐C.[30](#jah31627-bib-0030){ref-type="ref"} Therefore, given the favorable safety profile of statins and disastrous outcomes of CHD, the benefits of statin therapy clearly outweigh the risks of overtreatment in an era when CHD remains a world‐wide public health issue.[29](#jah31627-bib-0029){ref-type="ref"}, [30](#jah31627-bib-0030){ref-type="ref"}, [31](#jah31627-bib-0031){ref-type="ref"}

In addition, some studies reported that the ACC/AHA guidelines improved the alignment of statin eligibility.[5](#jah31627-bib-0005){ref-type="ref"}, [32](#jah31627-bib-0032){ref-type="ref"}, [33](#jah31627-bib-0033){ref-type="ref"} Recently, Ko et al.[27](#jah31627-bib-0027){ref-type="ref"} reported that, in the Korean population, the ACC/AHA guidelines would substantially increase the number of adults who would potentially be eligible for statin therapy and would recommend statin therapy for more adults who would have higher ASCVD events. Furthermore, a retrospective cohort study in an Asian population showed that the apparent overprediction of the pooled risk score could be a result of increased number of patients receiving statin therapy, which result would lead to a reduction of ASCVD events. The researchers also asserted that the pooled cohort risk score would be possibly appropriate for use in a primary care setting in the absence of validation of the pooled cohort risk score in an untreated population.[34](#jah31627-bib-0034){ref-type="ref"}

Regarding coronary imaging studies comparing the ACC/AHA and ATP III guidelines, the new guidelines showed better discrimination of coronary atherosclerosis than the ATP III guidelines, which suggests that the new guidelines will better predict future coronary events.[5](#jah31627-bib-0005){ref-type="ref"}, [6](#jah31627-bib-0006){ref-type="ref"}, [7](#jah31627-bib-0007){ref-type="ref"}, [8](#jah31627-bib-0008){ref-type="ref"} Pursnani et al.[5](#jah31627-bib-0005){ref-type="ref"} showed the superiority of the ACC/AHA guidelines in predicting CHD detected by CCTA in patients who presented to the emergency department with acute chest pain but who were not diagnosed with acute coronary syndrome. Johnson et al.[6](#jah31627-bib-0006){ref-type="ref"} also reported that the ACC/AHA guidelines better matched total plaque burden than the ATP III guidelines with only a modest increase in the number of patients who were assigned statins. More recently, 2 studies in Korea demonstrated that the ACC/AHA guidelines were more sensitive in identifying subjects with subclinical CHD and could better identify subjects with high‐risk individuals who could benefit from statin therapy.[7](#jah31627-bib-0007){ref-type="ref"}, [8](#jah31627-bib-0008){ref-type="ref"} In our study, the ACC/AHA guidelines showed better ability to detect CAC score progression than the ATP III guidelines (Table [4](#jah31627-tbl-0004){ref-type="table-wrap"}), which is concordant with the findings of previous studies. Furthermore, whereas previous studies mostly had a cross‐sectional design and used a single measurement of coronary atherosclerosis, precluding analysis of the temporal relationship between exposure and outcomes, we followed the change in the CAC score and used the CAC score progression as a surrogate marker of future CHD risk. The CAC score progression is predictive of an increase in all‐cause mortality, as well as hard and total CHD events.[9](#jah31627-bib-0009){ref-type="ref"}, [10](#jah31627-bib-0010){ref-type="ref"} In addition, considering that atherosclerosis progression is a dynamic and continuous process, monitoring of CAC progression by serial CAC scanning may be a more useful predictor of a patient\'s risk of future events than the baseline CAC score. To the best of our knowledge, this is the first report to compare the ability of the ACC/AHA guidelines and ATP III guidelines to discriminate CAC score progression in an asymptomatic Asian population.

Overall, 714 (57.3%) of subjects had no detectable CAC at baseline, of which 112 subjects (15.7%) developed incident CAC at follow‐up examination. Of 532 subjects (42.7%) with baseline CAC \>0, 201 subjects (37.8%) were categorized to progressor based upon their CAC root change. When we performed additional analysis in these subgroups according to baseline CAC, the ACC/AHA guidelines demonstrated better alignment with the incident CAC than the ATP III guidelines (*P* = 0.0044; Table S1). In participants with baseline CAC \>0, statin eligibility by both guidelines was associated with CAC progression; however, a statistical difference for the prediction of CAC progression was not observed between 2 statin guidelines (*P* = 0.7918; Table S2). These findings suggested that the ACC/AHA guidelines performed better especially in the prediction of incident CAC compared to ATP III guidelines.

The new ACC/AHA guidelines substantially lowered the cutoff for treatment to an evidence‐based threshold of 7.5%.[35](#jah31627-bib-0035){ref-type="ref"}, [36](#jah31627-bib-0036){ref-type="ref"} According to the ACC/AHA guidelines, statin treatment was regarded to be beneficial for reducing CVD events in subjects with a 10‐year ASCVD risk ranging between 5% and 7.5%.[1](#jah31627-bib-0001){ref-type="ref"} However, different populations may decide on very different thresholds because populations vary in their genetic backgrounds, lifestyles, and environmental factors, as well as their resources. We previously reported that, in our Korean cohort, the optimal cut‐off values for the 10‐year ASCVD scoring system for detecting significant coronary stenosis, CAC score \>100, and any plaque were 5.85%, 4.86%, and 4.26%, respectively.[8](#jah31627-bib-0008){ref-type="ref"} Similarly, in the current study, we found that the calculated optimal cut‐off value for detecting CAC score progression was 4.19%, which was lower than the recommended value of 5%.[1](#jah31627-bib-0001){ref-type="ref"} Although it has been suggested that the pooled cohort risk score seemed to overestimate CVD risk because of the lower cut‐off point, the relatively low cut‐off values in our results support the view that a cut‐off value of 5% for statin eligibility might not be too low in Asian populations. In addition, whereas the ATP‐III guidelines were only based on the 10‐year risk of CHD, the ACC/AHA guidelines broaden to comprise risk of all hard ASCVD, including CHD and stroke, using the Pooled Cohort Equations, which could contribute to the lower cut‐off value of the 10‐year ASCVD scoring system.[1](#jah31627-bib-0001){ref-type="ref"} However, our analysis demonstrated no statistically significant differences between the 2 risk scoring systems in the prediction of CAC score progression (Table [5](#jah31627-tbl-0005){ref-type="table-wrap"}). Therefore, the predictive value of 2 guidelines might not be derived solely from the difference of cut‐off values of the scoring system. Ideally, a comprehensive cost‐benefit analysis would help to estimate the clinical benefit of the treatment and set a reasonable cutoff in terms of cost‐effectiveness.

There are several limitations to this study. First, the retrospective nature of our study limits the establishment of causality. Second, we used the CAC score progression detected by MDCT, not actual coronary events, as the outcome measure to evaluate the accuracy of the statin guidelines. Therefore, although our results showed the superiority of the ACC/AHA guidelines over the ATP III guidelines for detecting CAC score progression, the absolute benefit of statin treatment according to these guidelines remains unclear because we did not investigate the actual occurrence of ASCVD. Third, although the definition of "clinical ASCVD" according to the ACC/AHA guidelines included peripheral artery disease and "CHD risk equivalents" in the high‐risk category included subjects with peripheral artery disease, abdominal aortic aneurysm, or carotid artery disease according to the ATP III guidelines, we could not obtain participant histories regarding peripheral artery disease, abdominal aortic aneurysm, and carotid artery disease. Fourth, the prescriptions for statin after study enrollment of the participants were not considered in the analyses, which might have resulted in promoted calcification of coronary plaque.[37](#jah31627-bib-0037){ref-type="ref"} Fifth, we could not determine whether subjects were representative of the general Korean population because participants were voluntarily recruited during routine health examinations, which might have introduced a selection bias. There remains a possibility that more high‐risk participants would be more likely to repeat their CAC measurement. Finally, the definition of CAC progression that we used might be problematic, given that there is still no consensus regarding this definition.[31](#jah31627-bib-0031){ref-type="ref"} However, it has been demonstrated that the best CAC progression model that can predict mortality is the SQRT method, which we used in our present study, and a SQRT difference of 2.5 provides the best fit for the data.[9](#jah31627-bib-0009){ref-type="ref"}

Despite these limitations, to the best of our knowledge, our study is the first to compare these 2 guidelines in terms of cardiovascular risk predicted by CAC score progression in an asymptomatic Korean population.

In conclusion, our results suggest that the new ACC/AHA guidelines provide better alignment of statin eligibility with CAC score progression than the ATP III guidelines. Further prospective, randomized, control trials that compare the accurate allocation of statins and the actual risk reduction by 2 guidelines are needed in the Asian population.
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